A Multicenter and Real-world Analysis of RC48-ADC in Patients With HER2-positive or HER2-low Expressing, Locally Advanced or Metastatic Breast Cancer
NCT06168227
·
clinicaltrials.gov ↗
COMPLETED
Status
150
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
Disitamb Vedotin
Sponsor
The First Affiliated Hospital with Nanjing Medical University